By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801



Company News
Orexigen (OREX)'s Mysimba Approved In Europe For The Treatment Of Obesity 3/26/2015 12:59:54 PM
Did Orexigen (OREX) Risk Its Future To Boost Stock Price? 3/4/2015 6:51:57 AM
Orexigen (OREX)'s Failure to Keep a Lid on it Prompts the FDA to Force a Second Study 3/4/2015 5:47:09 AM
Orexigen Therapeutics, Inc. (OREX) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014 2/25/2015 9:30:19 AM
Orexigen Therapeutics, Inc. (OREX) To Speak At The 2015 RBC Capital Markets Global Healthcare Conference 2/23/2015 7:58:36 AM
Orexigen Therapeutics, Inc. (OREX) To Host Full Year And Fourth Quarter 2014 Financial Results Conference Call And Webcast 2/23/2015 7:39:25 AM
Orexigen Therapeutics, Inc. (OREX) To Speak At The Leerink Global Healthcare Conference 2/9/2015 11:46:58 AM
Orexigen Therapeutics, Inc. (OREX) Provides Progress Update on Mysimba European Marketing Authorization 2/9/2015 9:41:19 AM
Orexigen Therapeutics, Inc. (OREX) To Present At The J.P. Morgan 2015 Healthcare Conference 1/8/2015 9:58:55 AM
Orexigen Therapeutics, Inc. (OREX)'s Mysimba (Naltrexone Hcl / Bupropion Hcl Prolonged Release) Receives Positive CHMP Opinion Recommending Approval For Weight Management In The European Union 12/19/2014 7:48:49 AM